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SUMMARY: 
This thesis demonstrates that erythrocyte carbonic 
anhydrase I is a useful tissue marker for thyrotoxicosis. 
Erythrocyte zinc, indirectly reflecting carbonic 
anhydrase content in erythrocytes ,has been shqwn to be 
a useful marker for the diagnosis of thyrotoxicosis and 
direct measurement of erythrocyte carbonic anhydrase I 
offers theoretical advantages. The immunological level 
of erythrocyte carbonic anhydrase I was measured by an 
automated immunoturbidimetric method using a centrifugal 
analyser. It correlated well with the standard method of 
radial immunodiffusion (r=0.981, p<O.OOOl). The 
recoveries reached 88-106% and the between-batch 
coefficien~s of variation were 6.3-9.9%. The analytical 
range was between 5 to. 50 mgjL. In the clinical study, 
the thyrotoxic patients' group showed diminished 
erythrocyte carbonic anhydrase I levels when compared to 
control group with minimal overlap. There was a 
significant negative correlation between pretreatment 
free triiodothyronine and erythrocyte carbonic anhydrase 
I (r=-O. 487 , p<O. 001) . The erythrocyte carbonic 
anhydrase I correlated well with erythrocyte zinc both 
before and during treatment (r=0.866, p<O.OOl, n=355). 
Due to the long life span of erythrocytes, rapid change 
of thyroid status after treatm~nt is not reflected by 
corresponding change in carbonic anhydrase I level, 
making it unsuitable to" monitor treatment. However, this 
delayed response enables the distinction of well 
established from transient thyrotoxic patients, such as 
those seen in transient thyroiditis. with the use of 
this automated assay , it is feasible to employ this 
tissue marker to supplement in vitro thyroid function 
tests in the diagnosis of thyrotoxicosis in routine 
clinical practice. 
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1. INTRODUCTION 
In vitro thyroid function tests (TFTs), being the 
major diagnostic tool in confirming suspicion of 
functional thyroid abnormalities, are adequate in most 
cases. However, there are situations in which these 
tests may prove inadequate or even misleading. 
Recently, analytical and performance guidelines of 
assays of free thy~oid hormones and thyrotropin were 
proposed by the American Thyroid Association committee 
for the routine investigation of thyroid dysfunction 
(Hay et al., 1991). Hay et al. also reviewed the 
strengths and weaknesses of methods measuring free 
thyroid hormones. Commonly encountered problem 
situations include abnormalities in serum 
concentrations of binding proteins like thyroxine 
binding globulin (TBG) or thyroxine binding p~ealbumin 
(TBPA), familial dysalbuminaemia, autoantibodies to 
thyroxine (T4) or triiodothyronine (T3), and 
nonthyroidal illnesses (NTIs) (Beckett & Seth, 1989; 
Hamburger, 1989; Hay et al., 1991). The assessment of 
thyroid function through studying its ' tissue effects 
may be a potential solution to these problems. 
Thyrotropin (TSH) can be regarded as a tissue marker 
for thyroid hormone as it reflects the pituitary 
response. to the circulating thyroid hormone level. 
Many enzyme activities ·in var·ious tissues are also 
known to aiter in thyrotoxicosis. Besides, sustained 
excess of thyroid hormone can lead to alterations in 
some haematological parameters. The choice of a 
suitable tissue marker is based on the ability to 
differentiate between the normal and diseased groups 
as well as the specificity and ease of quantitation. 
Erythrocyte zinc (EZN) has been shown to be a useful 
tissue marker for thyrotoxicosis. It indirectly 
measures the concentration of erythrocyte carbonic 
anhydrase isoenzyme B (ECAB), also known as carbonic 
- 2 -
anhydrase I (ECAI), the synthesis of which is affected 
by thyroid hormone. Therefore the direct measurement 
of erythrocyte carbonic anhydrase should provide a 
better indication of the tissue action in thyroid 
disorders. 
various methods have been described for the 
determination of the activity or the immunological 
level of CAI. None of them has been automated. This 
project aims to set up an automated assay for the 
determination of ECAI and look at its role , in the 
diagnosis of thyrotoxicosis. Immunoturbidimetric 
method is chosen because it requires least time and 
can be ~utomated using a centrifugal analyzer. 
In this thesis, the reasons behind the nec_essity of 
the use of tissue marker in adjunct with the existing 
TFTs were reviewed. Various tissue markers were 
described. A detail account of the carbonic anhydrases 
was included to understand the characteristics of the 
candidate marker (ECAI) • An immunoturbidimetric method 
for ECAI was set up , optimized and evaluated. A 
patient study was performed to see the relationship 
between ECAI and the existing in vitro TFTs such as 
free thyroid hormones in thyrotoxic patients. The 
results of ECAI and EZN of the thyrotoxic patients 
were investIgated to determine the correlation between 
these two tissue markers. Finally, the usefulness of 
ECAI in the diagnosis of thyrotoxicosis as well as the 
technical difficulties involved in the ECAI assay were 
discussed. 
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2 • BACKGROUND 
2.1 PROBLEMS ENCOUNTERED IN THYROID FUNCTION TESTS 
Thyroid dysfunctions can be classified by the 
severity of clinical findings, serum hormone 
levels (thyroxine, T4i triiodothyronine, T3i and 
thyrotropin, TSH) , the presence or ab~ence of 
thyroid autoantibodies, and physiologic and 
biochemical evidence of deficient or excessive 
thyroid hormone effect in target tissues (Helfand 
& Crapo, 1990). In vitro TFTs which measure 
circulating thyroid hormones or related hormone 
(TSH) are major diagnostic tools used to confirm 
clinical suspicion of functional thyroid 
abnormalities. ' These tests are adequate to 
con'firm diagnoses and monitor treatment of 
thyroid disorders in most cases. However, they 
have also led to the recognition of a growing 
array of situations in which euthyroid, or 
seemingly euthyroid, patients have abnormal TFT 
values. These include a variety of nonthyroidal 
illnesses (NTls), abnormal protein binding, drug-
induced alterations, pregnancy and assay 
interference (Beckett & Seth, 1989 i Hamburger, 
1989) . 
NTls have been found to have, a variety of effects 
~n thyroid physiology and, consequently on the 
use and interpretation of TFTs (Griffin, 1982; 
Griner, Panzer & Greenland, 1986; Fernandez-Ulba 
& Maxon Ill, 1989; Hamburger, 1989). The most 
common findings are reduced peripheral conversion 
of T4 to T3 resulting in decreased serum T3 and 
increased T4 levels, and elevation of reverse T3 
(rT3) levels possibly due to diminished 
degradation. Elevated T4 , decreased T3 , 
decreased TSH, and depressed TSH response to 
thyrotropin-releasing hormone (TRH) have all been 
- "4 -
reported in certain NTls (Griner, Panzer & 
Greenland, 1986). NTls may mimic true thyroid 
diseases or confound diagnosis of concomitant 
thyroid dysfunction. Malnutrition and severe 
systemic illnesses such as malignancy, myocardial 
infarction, liver failure, . renal ' failure, 
respiratory disorders and infections are 
important nonthyroid factors leading to 
abnormalities of TFTs. 
since 99.97% of T4 is bound to carrier proteins 
(thyroxine-binding globulin, TBGi thyroxine-
binding prealbumin, TBPAi and albumin), 
abnormalities in these binding proteins 
frequently produce abnormal total T4 results in 
euthyroid individuals (Chattoraj & Watte, 1986). 
Increased TBG concentrations may be due to 
oestrogen therapy (including oral contraceptives) 
or, occasionally, to an inherited excess; 
concomi tant increases in T4 and T3 are seen. 
Conversely, patient with hereditary TBG 
deficiency may have extremely low T4 and T3 
(Beckett & Seth, 1989). In addition, due to the 
wide interindividual biological variation in the 
concentration of thyroid hormone binding proteins 
and , hence the T4 c ' concentrat~9nJ an. individual 
with a significantly abnormal thyroid function 
may not be reflected by an 'abnormal' (i. e. 
outside reference limits) T4 result. T3 
measurements also suffer from the same problem, 
though not to the same extent as T4 (Chattoraj & 
Watt, 1986). Thus, total T4 and T3 measurements 
which measure both free and inactive protein-
bound hormone, are not reliable in many 
situations. 
A number of ' pharma co logic agents also interfere 
- 5 -
with the interpretation of TFTs of which the 
mechanisms 
Several 
of interaction are often 
commonly used drugs, 
complex. 
including 
oestrogens, affect TFTs in specific ways. Iodide 
(e.g. expectorants) and lithium can inhibit 
thyroid hormone secretion and cause clinical and 
biochemical hypothyroidism. Propranolol inhibits 
the deiodination of T4 and reduces plasma T3 
levels. Heparin administered in vivo reduces 
plasma free T4 (FT4 ) and free T3 (FT3 ) when 
measured by analogue-radioimmunoassay (analogue-
RIA) . Drugs such as phenytoin, salicylate, 
fenclofenac, carbamazepine and corticosteroids 
have complex effects, probably involving 
increased clearance of thyroid hormon~s, and 
decreased binding of hormones by plasma proteins 
(Beckett & Seth, 1989). 
During pregnancy, levels of plasma free thyroid 
hormones decrease, therefore appropriate 
trimester-related reference range~ are required. 
In the first trimester, a few patients may have 
low or undetectable levels of TSH. This may be 
a physiological response due to the weak 
thyrotrophic effect of the placental hormone, 
hu~an chorionic gonadotrophin, which reaches the 
highest concentration during the first trimester. 
Because of the high levels of TBG during 
pregnancy, total thyroid hormone measurements are 
of no value in assessing thyroid status (Beckett 
& Seth, 1989). 
There are a number of cases in which SUbstances 
present in plasma may interfere in the assay 
systems and produce spurious results. 
Genetically ~etermined variants of both albumin 
and pre-albumin have been described having 
- 6 -
different affinities for T4 and T3 compared with 
the normal proteins. These are uncommon, but are 
likely to give raised T4 and FT4 if routine 
methods of measurements are employed (Beckett & 
Seth, 1989). Free thyroid hormone measurements 
are now widely available to assess the biological 
active fraction of the hormone. The single-step 
'FT4 analogue-RIA' method involves the use of a 
labelled analogue which theoretically 
equilibrates only with FT4 pool and does not bind 
to binding proteins. However, there has been 
controversy over validity of this method, 
particularly in patients with NTI. The labelled 
analogue has been shown to be partially bound by 
albtimin so that changes in the .p~lasma 
concentration of this protein (and in substances, 
such as non-esterified fatty acids, which affect 
albumin-analogue binding) alter the FT4 result. 
For example, patients with hypoalbuminaemia have 
artefactually low FT4 whereas elevated free fatty 
acid levels can displace labelled analogue from 
albumin and .. consequently interfere with the 
assay (Erins et al., 1983; Stockight et al. 
1983; Beckett & Seth, 1989). The presence of 
endogenous thyroid autoantibodies or heterophilic 
antibodies may interfere in the immunoassays. 
The former types of antibodies compete for tracer ' 
binding with assay antibodies while the latter 
ones hinder binding of analytes to assay 
antibodies or link assay antibodies in the 
absence of analytes (Symons, 1989). 
other effects include end-organ resistance as a 
consequence of receptor defects or impairment of 
T4 deiodination in the pituitary or other tissues 
(e.g. liver). A wide range of TSH and thyroid 
hormone results are found depending on the 
- 7 -
particular defect in the patient's physiology 
(Beckett & Seth, 1989). 
2.2 A NEED FOR TISSUE MARKER VERSUS EXISTING THYROID 
FUNCTION TESTS 
An ideal test of thyroid function is expected to 
assess, ' specifically and sensitively, the 
metabolic ava~lability and impact of thyroid 
hormones within the cellular compartment of their 
target tissues (Al-awqati & Hassan, 1988). 
However, the existing in vitro TFTs only involve 
the measurement of circulating thyroid hormones 
or related hormone. To avoid pitfalls in TFTs, 
a working diagnosis of hypothyroidism or 
hyperthyroidism based on clinical findfngs is 
required. A history of drug ingestion may be 
helpful to explain misleading laboratory data. 
The implications of NTI must be considered 
(Hamburger, 1989). 
Problems exist in diagnosis of functional thyroid 
disorder can be illustrated in patients on 
amiodarone. Amiodarone is a drug with a variety 
of effects on the hypothalamic-pituitary-thyroid 
axis and can cause many problems in diagnosis. 
By inhibiting T4 to T3 conversion, it may 
increase T4 and decrease T3 levels, and by 
diminishing clearance of rT3, it causes elevation 
of rT3 in blood (Hamburger, 1989). These in vivo 
changes in thyroid hormone levels may not be 
associated with functional disorder. Also, this 
drug occasionally may cause hyperthyroidism or 
hypothyroidism as a side effect. Furthermore, in 
vitro assay interference is observed in certain 
thyroid hor1l1one assay methods. (Law et al., 
1988). Clinical assessment of thyroid status is 
also difficult as amiodarone blocks adrenergic 
- 8 -
function and symptoms may be attributed to 
deterioration in underlying cardiac condition. 
Many patients on amiodarone are chronically ill 
and thus have suppressed TSH levels. Hence, 
difficulties may be encountered in making a 
definitive diagnosis in certain patients. 
These problems may be solved if there is a 
parameter that reflects the tissue effect of 
thyroid hormone. Physiological tests such as 
Achilles tendon reflex and basal metabolic rate 
are either too complicated to perform or too 
difficult to interpret. TSH can be considered as 
a tissue marker for thyroid hormone under most 
circumstances as it reflects the p~tuitary 
response to the circulating thyroid hormone 
levels. It has no significant binding problem 
and is suppressed or elevated in thyrotoxic and 
hypothyroid patients respectively. This 
interpretation is however not applicable in 
patients with pituitary diseases~ In addition, 
many patients with NTIs and many apparently 
healthy subjects have unexplained low TSH 
concentration. In patients with pituitary 
disorders, there were reports of circulating 
f~nctionally inactive TSH molecules (Donald, 
1988). Thus TSH measurements, being a reliable 
in vitro TFT, is still not a foolproof method for 
assessing functional thyroid status. Therefore 
it is necessary to look for a clinically useful 
tissue marker which can reflect the actual 
thyroid status to supplement the existing in 
vitro TFTs. 
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2.3 CHOICE OF TISSUE MARKER AS AN ADJUNCT TO THYROID 
FUNCTION TESTS 
Alterations of many enzyme activities in various 
tissues are known to occur in thyrotoxicosis and 
in animals treated with an excess of thyroid 
hormone (Yotsumoto et al., 1982). Weinstein et 
al. reported in 1972 that the erythrocyte zinc 
content was affected by the prevailing functional 
thyroid status. Synthesis of ECAI was shown to 
be inhibited in hyperthyroidism and increased in 
hypothyroidism (Weatherall & Mclntyre, 1967). 
Other candidates have been described and these 
include serum ribonuclease (Leeper, 1963), serum 
angiotensin-converting enzyme (Yotsumata et al., 
1982), serum 1'-glutamyl transpeptidase ,(-Azizii ' 
1982), serum ferritin (Takamatsu et al., 1985), 
erythrocyte Ca2+ -ATPase (Dube et al., 1986) and 
serum alkaline phosphatase isoenzyrnes (Tibi et 
al., 1989). Besides, sustained endogenous 
averpraductian .of thyraid harmone can lead ta 
haematalagical changes, such as micracytasis, 
elevated haemaglabin A2 and accasianally a slight 
elevatian .of haemaglabin F (Kendall and 
Bastamsky, 1981). EZN and ECAI have alsa been 
pramated as tissue ~arkers ~n thyrdid disarders 
(Weinstein et al., 1972; Pangara et al., 197~; 
Swaminathan et al., 1976; Bremner & Fell, 1977; 
Nishi et al., . 1980; Aihara et al., 1984; 
Buchinger, et al., 1988). 
2.3.1 ERYTHROCYTE ZINC 
Zinc in the erythracyte is present mainly as 
zinc containing enzymes and carbanic anhydrase 
(CA) is the major zinc metalloenzyme in 
erythracyte. ECAI was shown ta be grossly 
reduced in hyperthyroidism and elevated in 
hypothyraidism (Weatherall. & Mclntyre, 1967). 
- 10 -
Thus EZN, which reflects the change in carbonic 
anhydrase, can be viewed as reflecting a tissue 
effect of thyroid hormone (Shek, 1989). 
However, the delayed response of EZN to rapidly 
changing thyroid status has limited its 
application in monitoring patients on 
antithyroid treatment. Also, the use of 
elevated EZN in diagnosing of hypothyroidism is 
questionable as there are many patients having 
elevated EZN without any clinical or 
biochemical evidence of hypothyroidism. 
Despite the above disadvantages, EZN is still 
a useful tissue marker in hyperthyroidism. It 
has been shown to reflect the functional 
thyroid status for the previous few months and 
being capable of distinguishing transient from 
well established hyperthyroidism as well as 
confirming a recent episode of transient 
hyperthyroidism (Shek, 1989). EZN is usually 
determined by atomic absorption 
spectrophotometry. The method cannot be 
automated and therefore has limited its use in 
the diagnosis of thyroid disorders in routine 
clinical practice. 
·2 .3 .2 ERYTHROCYTE CARBONIC ANHYDRASE ISOENZYME 
EZN, as described above, is only an indirect 
measurement of the changes in erythrocyte 
carbonic anhydrase. The main ECA isoenzymes, 
ECAI, ECAII and ECAIII, found in adult 
erythrocytes are approximately in the 
proportion of 86:13:1 respectively (Carter et 
al., 1984). The use of ECAI as tissue marker 
may be a better indication of the tissue effect 
in thyroid abnormalities since ECAI is 
consistently reduced in established 
- 11 -
thyrotoxicosis. Its quantitation has been 
suggested as an adjunct to the usual TFTs 
(Kendall and Bastomsky, ' 1981) . In 
hypothyroidism the opposite effect is observed 
i.e. elevated ECAI. Apart from thyroid 
diseases, ECAI and EZN may be abnormal in other 
disease states which are shown in Table 1. In 
most cases, their values tend to be elevated 
which hinder their applications in the 
diagnosis of hypothyroidism. ECAI has been 
determined by various techniques such as 
Ouchterlony double diffusion tests, single 
radial immunodiffusion (RID) test, starch gel 
electrophoresis, 180 exchange method, enzyme 
linked immunosorbent assay (ELISA). H~wever, 
the above techniques are time consuming and may 
not be suitable for routine purpose. This 
project aims to determine whether it is 
possible to measure ECAI using 
immunoturbidimetric method. It seems that 
immunoturbidimetric method, which can be 
automated, is the most feasible method for 
determining ECAI to serve as tissue marker in 
thyroid abnormalities in routine clinical 
practice. 
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TABLE 1: CONDITIONS AFFECTING ERYTHROCYTE ZINC 
& CARBONIC ANHYDRASE I CONCENTRATION 
Pregnancy & oral 
Anaemia 
Megaloblastic 
Iron deficiency 
Thalassaemia 
Sickle cell 
Acute 
Liver . disease 
Liver cirrhosis 
Kidney disease 
Lung disease 
Emphysema 
Tuberculosis 
Down's syndrome 
Zinc deficiency 
Inc: Increased 
Dec: Decreased 
N Normal 
cqntraception 
(adapted from Shek, 1989) 
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ECAI EZN 
Inc/N 
Inc Inc 
Inc 
Inc 
Inc/Dec 
N 
N 
Inc 
Inc/N 
Inc 
Inc 
Inc 
Dec Inc 
N 
3. CARBONIC ANHYDRASE 
To understand the characteristics of this potential 
thyroid tissue marker, the structures, distribution, 
mechanisms of action, genetics and regulation, as well 
as physiological and clinical roles of the various 
isoenzymes will be reviewed in this section. ' 
3.1 HISTORY AND BACKGROUND 
Carbonic anhydrase (carbonate dehydratase, E.C. 
4 . 2 . 1. 1. ) was first described by Meldrum and 
Roughton in 1933 (Meldrum and Roughton, 1933; 
Maren TH, 1967). It was the first metalloenzyme 
to be discovered. It is a water-soluble zinc 
protein of 30000 daltons and contains one zinc 
ion per enzyme molecule (Tashian and Hewett-
Emmett, 1989; Rockett, 1985). In the 1930s, 
interest in the enzyme was minimal and largely 
confined to its role in respiratory physiology. 
Interest however grown abruptly with the latter 
finding of carbonic anhydrase (CA) in the stomach 
and kidney and in many other secretory organs of 
vertebrate and invertebrate classes (Rockett, 
1985). 
CAs are found in almost all org.anisms, and are 
notable for the extremely high turnover numbers 
(some exceeding 1 x 106 . sec-l) of the high 
activity forms, ranking them among the most 
efficient enzymes known. They are also 
distinctive because of extensive diversity in 
both the cellular distribution and in the 
putative or established biological functions of 
the seven CA isoenzymes now known to occur in 
higher vertebrates. Some of the CA genes are 
expressed in certain cells of nearly all tissues, 
whereas others appear to be more limited in their 
distribution. Because of such diversity in 
- 14 -
expression and function, the CA isoenzyme system 
is an excellent model for the study of molecular 
processes and patterns underlying the evolution 
and expression of genes derived from a common 
ancestor (Tashian, 1989). 
3.2 CARBONIC ANHYDRASE ISOENZYMES 
There are at least seven CA isoenzymes known to 
occur in higher vertebrates. Some of their 
selected features are summarised in Table 2 
(Tashian, 1989) . 
3.2.1. STRUCTURE AND DISTRIBUTION 
Most of the chemical studies of CAs have been 
on products of mammalian origin. ." ~' Three 
isoenzymes have been isolated in crystalline 
-
form and a considerable number of structural 
and enzymatic activity studies have been 
carried out on them (Deutsch, 1984). They are 
highly homologous in their primary, secondary 
and tertiary structure and consequently 
physicochemical characteristics (Notstrand et 
al., 1975). Two common forms exist in the 
erythrocytes, one with weak enzymatic 
activities (CAlor CAB), the other with high 
activities (CAll or CAC). They have 46% ". 
homology in the amino acid sequence (Fig 1) 
and the homologies are most pronounced for the 
residues forming active sites of the enzyme. 
CAllI, another low activity enzyme, is found 
in abundance in red skeletal muscle. The 
other isoenzymes (CAlV, CAV, CAVl and CAVIl) 
seem to be more restricted in their cellular 
or subcellular expression. Although the 
membrane-bound CAIV form is known to occur in 
kidney (brush border of luminal cells) and 
lung (endothelium), it seems likely that it 
- 15 -
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will be found in other tissues as well 
(Tashian, 1989). 
in the structures 
Due to the high homologies 
of these enzymes , it is 
likely that they all arose from the same 
ancestral gene (Tashian, 1989). 
3.2.2. GENERAL MECHANISMS 
Carbonic anhydrase is important in the 
transport of carbon dioxide. It catalyses the 
reaction shown in Eq (1) • 
Kt 
CO2 + H2O ~ H+ + HCO -3 (1) 
~t phys~ological pH, the uncatalysed reaction 
is relatively slow. A hydroxide dep·endent 
mechanism is much faster but only proceeds in 
high OH- concentration (alkaline pH) (Eq. 2). 
The carbonic anhydrase, with the zinc ion in 
the active site, ensures a high OH-
concentration at the active site by forming a 
Zn.UH complex, hence allowing the rapid 
progress of the reaction at physiological pH. 
(2) 
It provides a ready source of these ions for 
secretory and exchange processes across cell 
membranes. 
3.2.3 GENETICS AND REGULATION 
In terrestrial vertebrates, the CA system 
comprises at least seven genes (Table 2). 
Four of these (coding for CAI, CA!I, CA!!I and 
CAVIl) have now been fully or partially 
characterize~, and with the exception of human 
CAI, which has a large intron in the 5 I 
untranslated region, they all appear to have 
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seven exons, with the six introns at the same 
positions, and range in size from 9.8 kb 
(human CAVIl) to 17 kb (chicken and human 
CAll) (Tashian, 1989). The human CAI, CAll 
and CAllI genes are linked on chromosome 8, 
whereas the genes for CAVI and CAVIl are 
located on chromosome 1 and 16 respectively. 
In view of the dispersion of the CA genes to 
at least three chromosomes , it will be of 
interest to determine the chromosomal 
locations of membrane-bound CAlV and 
mitochondrial CAV genes (Tashian, 1989). 
According to available primary structure 
information the three cytoplasmic iso~nzymes 
(CAI, CAll and CAllI) seem to be equally 
distant from each other from an evolutionary 
viewpoint, thus leading to the assumption that 
they are the result of two gene duplications 
occurring close together in time. CAV and 
CAVI appear to have a lower degree of identity 
with the cytoplasmic isoenzymes (Bergenhem and 
Carlsson, 1990). A number of variants of the 
human CA isoenzymes are now known, and some of 
these have been reported to occur as 
widespread polymorphism (Lee et al., 1985). 
About 20 electrophoretic variants of human CAl 
and eight variants of human CAll have been 
found after screening of haemolysates from 
many different human populations (Jones and 
Shaw, 1983). The discovery of such variants 
has not been clinically significant. However, 
these variants may prove of value as genetic 
markers in relation to popUlation origins, 
movements and adaptations (Kendall, 1979). 
- 19 -
3.2.4. PHYSIOLOGICAL AND CLINICAL ASPECTS 
Early studies indicated that the activities or 
levels of CAI and CAII in various mammalian 
tissues could be influenced by hormones, 
particularly steroids, in a number of 
different tissues in various species (Shepherd 
& Spencer, 1985). These include thyroxine 
(erythrocytes), sex hormones (endometrium, 
accessory sex glands), cyclic AMP-mediated 
action of epinephrine (erythrocytes), and 
prolactin (pituitary gland) (Tashian, 1989). 
Recently, it was shown that growth hormone 
has a differential effect on the levels of 
CAIII in -rat liver' in which the amount of 
CAIII in the male can be 15-20 times greater 
than in the female. 
Changes in the levels of CAIII in rat skeletal 
muscle brought about by hypo- and hyperthyroid 
conditions seem to depend on the type and 
amounts of the different fibres. The increase 
in CAllI, resulting from thyroidectomy was due 
not only to an increase of CAllI in the slow-
twitch type 1 fibers (which normally express 
CAllI), but also in a subtype of type 2A 
f ibers (which do !lot normally express _CAllI) ' 
, (Jefferyetal.~ 1987; Tashian, 1989).: Also, 
thyroid disorders are known to alter fibre 
composition of human muscle (Jeffery et al., 
1987) . 
The most commonly assayed CA isoenzyme in 
human tissue is ECAI which is well established 
of being lowered in hyperthyroidism. These 
lowered values have been assumed to be related 
to circulating thyroid hormone levels 
(Shepherd and Spencer, 1985). However, extra 
20 -
attention has to be given to the 
interpretation of the ECAI results in cases of 
pregnancy as the total circulating 
concentrations of steroid hormones as well as 
thyroid hormones are known to alter. 
CA!! ,deficiency in humans has recently been 
identified as the putative cause of a 
hereditary, autosomal recessive form of 
osteopetrosis with renal tubular acidosis and 
cerebral calcification (Dodgson et al., 1988; 
Tashian, 1989). Although all individuals who 
were homozygous for this defect have medical 
problems of great severity" erythrocyte CA!! 
dbes not appear to be essential for su~vival, 
since all of these patients have survived to 
maturity (Dodgson et al., 1988). 
other examples of hormonal control of CA have 
been the recent demonstration of androgen 
regulation of CA!! in rat prostate, and the 
modulation of CA!! by calcium-regulating 
hormones (calcitonin and parathyroid hormone) 
in human erythrocytes (Tashian, 1989). 
- 21 -
4. ANALYTICAL METHODS FOR MEASUREMENT OF ERYTHROCYTE 
CARBONIC ANHYDRASE 
Numerous methods have been developed for the 
determination of the activity and the immunological 
level of carbonic anhydrase. The techniques employed 
for the estimation of enzyme activity include the 
assay of esterase activity described by Armstrong et 
al. (Armstrong et al., 1966; Kondo et al. 1987), the 
specific immunosorbent method for the specific 
activity (Kondo, et al., 1984), and the IS0_ exchange 
method for the hydration velocity of CO2 catalyzed by 
carbonic anhydrase (Dodgson & Forster 11, 1983; 
Dodgson, et al., 1988 & 1990). Most techniques 
involve cell lysis and assay of the enzyme activity 
over a pH range (Maren, 1967). Itada and Forster 
determined the carbonic anhydrase activity of intact 
erythrocytes by monitoring the loss of ISO from 12C180160 
dissolved in solution using mass spectrometry in the 
IS0_ exchange method (Itada & Forster, 1977). On the 
other hand, carbonic anhydrase concentration can be 
determined immunologically by more commonly used 
analytical techniques; for o- instance, the agarose, 
polyacrylamide, or starch gel electrophoresis 
(Drescher, 1978; Murch et al., 1986; Dodgson, et al., 
-1988); Ouchterlony technique (two-dimensional double 
_ immunodiffusion) (Ouchterlony, 1949; Auton et al., 
1976; Dodgson et al., 1988); single radial 
immunodiffusion (RID) (Funakoshi & Deutsch, 1970; 
Auton, et al., 1976; Yamakido et al., 1982; Goriki et 
al., 1982; Kondo et al., 1984 and 1987) and enzyme 
linked immunosorbent assay (ELISA) (Kato & Mokuno, 
1984; Shepherd et al., 1985; Shepherd & Spencer, 
1985) . 
Immunoturbidimetric methods, however, have not been 
available. This methodology requires least time, and 
can be automated using a centrifugal analyzer. Thus, 
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it is a potential method of choice for the estimation 
of ECAI for the diagnosis of thyrotoxicosis on routine 
basis. 
This project aims to set up an immunoturbidimetric 
assay for the measurement of ECAI and to investigate 
its use in the diagnosis of thyrotoxicosis. The test 
method is optimized and evaluated in different aspects 
including assay parameters, working range of the 
method (linearity), stability of the reagent, expected 
reference range, amount of error caused by interfering 
substances, precision (within-run & between-run) and 
accuracy of the method (determined by comparison of 
results to those obtained by a standard method -RID) . 
Also, a ' study of groups of normal and thyr·otoxic 
subjects is included to assess its use to diagnose 
thyrotoxicosis. 
4.1 DETERMINATION OF ECAI USING IMMUNOTURBIDIMETRIC 
ASSAY 
This section includes the' principle of 
immunoturpidimetry, the preparation of blood 
specimen, the set-up, optimization and evaluation 
procedures of the immunoturbidimetric assay, and 
the protocols of the determination of the 
erythrocyte parameters . such as haemoglobin (Hb) 
·concentration . and mean . cell haemoglobin 
concentration (MCHC) required for the calculation 
of ECAI concentration. 
4.1.1. PRINCIPLE OF TECHNIQUE 
Interaction of light with particles 
The phenomenon of light scattering is the 
basis of the principle of nephelometric or 
turbidimetric assays. When a collimated beam 
of light strikes a particle in suspension, 
some light is reflected, some is scattered, 
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some is absorbed, and some is transmitted. 
Nephelometry is the measurement of the light 
scattered by a particulate solution while 
turbidimetry measures light scattering as a 
decrease in the light transmitted through the 
solution. 
In nephelometry, the nature of how light is 
scattered by' a homogeneous particle suspension 
can be classified into three types. If the 
wavelength, A, of light is much larger than 
the size of the particle (d) (i.e. d < 0.1 A), 
the light is symmetrically scattered around 
the particle,with a minimum in the intensity 
tif the scatter occurring at 90 degrees ~ o the 
incidence beam, as described by Rayleigh (Fig. 
2, A) (Kaplan & Pesce, 1989). 
If the wavelength of the incident light is 
much smaller than the size of the particle (d 
> 10 A), most of the light will be scattered 
forward because of destructive out-of-phase 
backscatter, as described by the Mie theory 
(Fig.2, B) (Kaplan &' Pesce, 1989). 
If, however, the wavelength of light is 
approximately equal to the size of the 
particles (such as antigen-antibody 
complexes), more light appears scattered in a 
forward direction than in a backward direction 
when the detection angle, e, approaches zero 
(Fig. 2, C), as described by Rayleigh-Debye 
scatter (Kaplan & Pesce, 1989). 
For both the Rayleigh and Rayleigh-Debye light 
scattering, the intensity of scattered light 
is always proportional to the intensity of 
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A SMAll PARTICLES 
· lIGHT SCATTERED SYMMETRICAllY 
BUT MINIMALLY AT 900 (RAYLEIGH) 
d<O.l A 
B VERY LARGE PARTICLES 
·lIGHT MOSTlY SCATTERED FORWARD 
(MIE) 
~~. 08-:)-0' 
d>A 
C LARGE PARTICLES 
·LlGHT SCA TIERED PREFERENTIAllY 
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Fig. 2 Effect of particle size on scattering of incident light 
in n homogeneous solution. (Fronl Gall/die. J: III Kap/all. L4. 
and Pesce. AJ. editors: Nonisotopic a/terllatil:es to radioimmu-
noassay. New York. /981. Marcel Dekker. Inc.) 
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incident light and inversely related to the 
fourth power of the light wavelength (Sheehan, 
1990). One of the most common applications of 
light-scattering analyses is the measurement 
of antigen-antibody reactions. As most 
antigen-antibody complex systems are 
hete~ogeneous with particle diameters ranging 
from 250 to 1500nm and the wavelengths used in 
most light-scattering analyzers are 320 to 
650nm, the scatter seen is essentially 
Rayleigh-Debye, with the Rayleigh scatter 
being the blank scatter. Therefore, the use 
of a laser light source and a forward angle 
detection (0 = 15 to 90 degrees) of scattered 
light would produce greater signals and,.,. .·hence 
greater sensitivity in nephelometry. 
Kinetics of fluid phase precipitation 
The interaction of antigen and antibody in 
solution depends on numerous · factors, most 
important of which is their relative 
concentrations. When the antibody is in 
excess and the antigen is polyvalent, there 
will be secondary rearrangement of bindings 
between the two species and cross-linking of 
the antigen-antibody complexes to form a 
lattice slowly. At this stage, the complex is 
large and can produce Rayleigh-Debye 
scattering of visible light. If the antibody 
concentration remains in excess, the secondary 
rearrangement continues, which eventually 
forms aggregates and even a visible 
precipi tat ion . As shown in Fig. 3, maximal 
lattice is formed at the antigen- antibody 
equivalence zone (Sheehan, 1990). The lattice 
aggregates will be broken up to large amount 
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FIGURE 3'. · The quantitative precipi-
tin curve generated by .adding increas-
ing amounts of antigen'" to a solution of 
antibody and measuring antibody-anti-
gen complexes by r:tephelometry. (Re-
printed from Ref. 3. p. 123. by courtesy 
of Marcel Oekker. Inc.) 
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JUy. New York. /98/. Murc:e/ Dd:.kt:r. /IIC.) 
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of smaller antigen-antibody complexes in the 
addition of more antigen or antibody to the 
lattice. It should be noted that for any 
antibody concentration two different antigen 
concentrations can produce the same amount of 
lattice and light scattering signal. 
Nephelometry is often used to measure antigen 
concentrations in the presence of excess 
antibody so that the light scattering signal 
produced is proportional to the antigen 
concentration in test specimens. It is 
important to prevent a reaction in antigen 
excess which will result in a falsely low 
'signal by doing an extra dilution on the test · 
specimen. 
Background interference is often encountered 
in nephelometric assay. The sources of this 
background scattering include proteins and 
lipoproteins in the specimen, particles or 
dust present in the reagents, or stray light. 
This background signal can be minimized by . 
using nephelometric grade antisera, filtered 
reagents and a high dilution of the specimens. 
The factors . controlling the ' antigen-antibody 
interaction are ' the antiserum affinity and 
avidity, the buffer, pH, and ionic strength of 
the assay solution. Besides, the interaction 
can be greatly enhanced by - the presence of 
nonionic, hydrophilic polymers. These polymer 
molecules being more hydrophilic than the 
antigen or antibody molecules, attract water 
molecules from the latter molecules and hence 
increase the chance of antigen-antibody 
reaction. 
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Polyethylene glycol (PEG) is now routinely 
used for this purpose to speed up the reaction 
rate, increase the slope of the precipitin 
curve in the antibody excess zone, and push 
the equivalence zone to a higher antigen 
concentration. It is especially effective 
with low-avidity antisera (Sheehan, 1990). 
The use of this enhancer will result in 
nephelometry of considerably greater 
sensitivity, wider detection range, and 
quicker assay. However, the addition of PEG 
can also cause nonspecific precipitation of 
macromolecules such as proteins, lipoproteins, 
heparin, immunoglobulins, and endogenous · . 
immune complexes. Therefore the amount _"of PEG 
added must be carefully controlled. 
Instrumentation 
Turbidity is a measure of the reduction in 
the light transmission caused by particle 
formation, and it quantifies the residual 
light transmitted (Fig. 4) (Kaplan & Pesce, 
1989) . The instrumentation required ranges 
from a simple spectrophotometer to a fully 
automated discrete centrifugal analyzer. 
1?e~ause this technique .. m~asures a decrease in 
transmitted· light, the sensitivity of 
turbidimetry is limited by the photometric 
accuracy and sensi ti vi ty of the instrument. 
Table 3 (Sheehan, 1990) includes examples of 
some commercial clinical instruments available 
for light-scattering analysis. 
4.1.2. COLLECTION AND HANDLING OF BLOOD SPECIMEN 
7 . 5 mL of venous blood was collected from 
patients ~nd normal subjects. 5 mL was 
transferred to a heparin tube and 2.5 mL was 
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Table 3: Automated Clinical Instruments Available for Light-Scat~ering Analysis 
Technicon AlP 
Nephelometer N(90 ) 
(N) (angle) or 
turbidimeter 
(T) 
Endpoint (E) or E + blank 
kinetic (K) 
analysis of 
reaction 
Light source 
(A ,rm) 
Calibration 
Satrples/hour 
Reaction time 
Sensitivity 
Precision (CV) 
Uithin-run 
Between-run 
Capital outlay 
Original 
monitoring 
capability 
Other type of 
analysis 
Mercury arc 
(357 rm) 
Standard curve 
120 . 
10 min 
5 mg/L 
2%-5% 
5%-10% 
++ 
o 
++ 
Behring 
Autolaser LH 
N(5 -12 ) 
E + blank 
Beckman 
Automated 
ICS 
H(70 
Reaction Rate 
Analyzer 
T 
K or E 
Laser 
(632.8 rm) 
Tungsten lamp Variable: 
(400-550 rm) UV to 700rm 
Standard curve ,Single point, 
reagent lot reagent lot 
120-240 
1 hour (no 
PEG) 
+ 
+ 
30-50 
30 sec 
1 mg/L 
2X-5% 
5%-10X 
+++ 
+++ 
+ 
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Standard curve, 
re~gent lot 
20-40 
1-2 min 
(Kinetic) 
"+++ 
+ 
+++ 
Centrifugal 
Fast Analyzer 
T 
K or E 
Variable: 
UV to 700rm 
Standard curve, 
reagent lot 
300 
1-2 min 
(Kinetic) 
++++ 
+ 
++++ 
anticoagulated with EDTA. The heparinized 
sample was used for ECAI and haemoglobin (Hb) 
measurements while the EDTA sample was used 
for measurement of mean cell haemoglobin 
concentration (MCHC). 
4.1.3. PREPARATION OF HAEMOLYSATE 
Equipment & Reaqents 
1. BeckmanR J-6B Centrifuge 
2. Heraeus sepatechR Biofuge A 
3. Isotonic magnesium chloride solution 
(112.7 nunoljL) 
Mg Cl2 • 6H20 (mw 203.23) 
D.W. 
Procedures 
114.56g 
up to 5L 
1. The heparinised sample was centrifuged at 
3000 rpm in a Beckman J-6B Centrifuge for 
10 minutes. 
2. 1 mL of cells taken from the bottom of the 
tube & resuspended in 4 mL of isotonic 
MgCl2 solution. 
3. The resultant suspension was centrifuged at 
2000 rpm for 10 minutes. The supernatant 
was aspirated and MgCl2 re-introduced. 
This washing cycle was repeated three 
times. 
4. The washed packed cells were lysed with 2 
volumes of iced D.W. by freezing at -20°C 
and thawing in 37°C. 
5. The haemolysate preparations were 
centrifuged at 9000 rpm (- 10000g) in 
Heraeus sepatechR Biofuge A for 10 minutes 
to remove cell stroma. This stock 
haemolysate was frozen at -40°C before 
analysis. 
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4.1.4. MEASUREMENT OF HAEMOLYSATE CAI 
Materials 
(include those used in optimisation procedure) 
1. CAI antiserum - anti-human CAI, economic 
grade, code PE046, The 
Binding site Ltd. 
2. CAI standard - sigma CAI (EC 4.2.1.1.) -
human erythrocytes,C4396, 
pI-6.6, electrophoreti-
cally purified, dialyzed 
and lyophilized, Sigma 
Chem. Co. 
stock standard, 1000 mg/L is prepared by 
dissolving 1mg CAI in 1 mL O.lM PBS- . 
Aliquoted (100 J.LL) & stored in -70°C. 
Further dilution of CAI stock is done using 
1% BSA as diluent. 
3. Bovine serum albumin (BSA) , 1% 
Albumin, Bovine. A-7888 Lot 99F00121i 
initial fractionation by cold alcohol 
precipitation, RIA grade, Fraction Vi 96-
99%, sigrna Chem. Co .. 
0.5g made up to 50 ml using 0.9% NaCI. 
4. Phosphate buffered saline (PBS) ,0 .1M, pH7. 4 
NaCI 8.1g 
NaH2P04 • 2H20 
Na2HP04 
D.W. 
0.2808g 
1.644g 
up to 1L 
- pH adjusted to 7.4, millipore 0.22 J.Lm 
filtered. 
5. PEG 6000, 10% 
Polyethylene glycol 6000 for biochemistry, 
BDH. 
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50g made up to 500mL using O.lM PBS. 
- millipore 0.22 ~m filtered. 
6. Control haemolysate samples 
A known thyrotoxic patient (P) and a normal 
subject (N) were chosen by reviewing the 
clinical history, TFT and/or EZN results. 
7. Triton X-lOO, 0.1% 
TritonR X-lOO, C34H620 11 , mw= 646.87 g/mol, 
Art 8603, Merck. 
100 ~L made up to 100mL using 0.9% NaCl. 
Instrumentation 
1. Bausch & Lomb SpectronicR .,. ·-2000 
Spectrophotometer System. 
2. Cobas Bio centrifugal analyser (F. Hoffmann 
La Roche & Co., Basle, Switzerland). 
Methods 
1. Haemoglobin (oxyhaemoglobin) spectrum . . was 
determined by the B & L SpectronicR 2000 so 
· as to select a suitable wavelength (with 
minimal ab inter~erence) for the detection 
. and monitoring of the immunoturbidimetric 
reaction. 
2. Cobas Bio centrifugal analyser was used to 
measure the turbidity formed from the 
antigen-antibody reaction between CA! 
standards and anti-CA! antibodies in a 
phosphate buffer containing an appropriate 
amount of PEG as accelerator. New cuvette 
rotors were used to prevent high background 
light scattering. The reaction was 
monitored to study the kinetics in the 
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optimization procedure. 
The absorbance change at endpoint was 
used to calculate the concentration of CAr 
in the sample using a best fit standard 
curve derived using the DENS ' (Data 
Evaluation for Non-linear Standard curves) 
plot function of the Cobas Bio analyser. 
The DENS/Plot program was designed to 
evaluate non-linear standard curves using 
3, 4, 5 or 6 standards. 
4.1.5. OPTIMIZATION PROCEDURE 
The procedure was optimised by studying the 
kinetics of reaction for the fol~owing 
factors: (i) wavelength, (ii) concentration of 
antibody, (iii) concentration of PEG-, ( i v) 
sample volume, (v) temperature and (vi) 
reaction time. Parameter settings listed in 
Table 4 which were used in the first trial 
run, were modified from Cheung & Swaminathan 
(Cheung & Swaminathan, 1989). 
The stock CAr standard was diluted by 1% BSA 
to give working standards with concentrations 
ranging from "5 to 100 mg/L. Control 
haemolysates \ from the selected thyrotoxic 
patient and the normal subject were diluted 
with distilled water. 
Wavelength of 650 nm was selected for trial 
followed by 450 nm. Antibody dilutions 
including 1/4 and 1/8 were tested against CAr 
standard concentrations of 25, 50 and 100 
mg/L. The PEG concentration was then 
optimised by looking at the reaction kinetics 
between CAr standards and different antibody 
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Table 4 Preliminary parameter listing for the 
measurement of CAI concentration in 
haemolysate using cobas-Bio centrifugal 
analyser (Roche). 
1. UNITS mg/L 
2. CALCULATION FACTOR 5000 
3. STANDARD 1 CONCENTRATION 0 
4. STANDARD 2 CONCENTRATION 0 
5. STANDARD 3 CONCENTRATION 0 
6. LIMIT 0 
7. TEMPERATURE ( °C) 37 
8. TYPE OF ANALYSIS 5 (ENDPOINT) 
9. WAVELENGTH (nm) 650 
10. SAMPLE VOLUME (J.LL) 30 
11. DILUENT VOLUME (J.LL) 10 
12. REAGENT VOLUME (J..LL) 150 
13. INCUBATION TIME (sec) 10 
14. START REAGENT VOLUME (J.LL) 0 
15. TIME OF FIRST READING (sec) 1.0 
16. TIME INTERVAL (sec) 30 
17. NUMBER OF READINGS 30 
18. BLANKING MODE 1 
19. PRINTING MODE 1 
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dilutions. The sample volumes of 30, 25, 20 
and 15 J.LL were tried to select the optimal 
sample volume and antibody dilution. Besides, 
the optimal reaction temperature and time 
would be evaluated according to the reaction 
kinetics. After all the factors have been 
investigated, an optimized assay protocol 
would be figured out for further evaluation 
and patient study. 
4.1.6. EVALUATION EXPERIMENTS 
Evaluation experiments of this assay were 
performed and included the stability of the 
reagents, working range of the method 
(linearity), precision (within-run, between-
run), amount of error caused by cross-
reactivity, recovery ,accuracy (determined 
by comparison of results to those obtained by 
an established method - RID), and expected 
reference range. 
stability 
The stability of reagents, calibrators, and 
control materials was verified by evaluating 
the analytical performance over a period of 
time. 
Linearity 
The linearity of the method was determined 
using the optimised protocol, with the use of 
aqueous CA! standards of concentrations of 
1.25, 2.5, 5.0, 10.0, 20.0, 30.0, 40.0, 50.0, 
60.0, 70.0, 80.0 and 90.0 mg/L. 
Linearity experiments were also performed 
using a dilution series of control 
haemolysates N & P containing the biological 
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matrix. They were diluted with Triton X-lOO 
and distilled water according to Table 5. The 
comparison between Triton X-lOO and distilled 
water will provide information whether 
detergent, a commonly used haemolysing agent, 
can affect the assay and preclude its 'use in 
the haemolysate preparation. 
Precision 
In the precision study, both the within-run 
and the between-run components of variation 
were estimated to evaluate short- and longer-
term analytical variations. It involved the 
use of 3 levels namely low (L), medium (M) arid 
high (H) of ECAI for the within-run an.cl the 
use of 2 levels including Land H of ECAI for 
the between-run precision. stock P ' and N 
haemolysates were used to prepare L, M and H 
as follows: 
(i) L: 
(ii) H: 
(iii) M: 
0.25% haemolysate P in 
D.W. from stock. The 
resultant haemolysate was 
centrifuged at 10000g for 
10 minutes to remove cell 
debris. 
0.25% haemolysate N in 
D . W . from stock. The 
resultant haemolysate was 
centrifuged at 10000g for 
10 minut~s to remove cell 
'debris. 
Equal volume of Land H 
were mixed to obtain a 
medium level of ECAI. 
Fifteen 100 ~L aliquots of each level L, M, H 
were analyz'ed for ECAI using the optimized 
protocol in the within-run precision 
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Table 5 Preparation of control haemolysates for linearity 
study 
VOLUME of 0.25% VOLUME OF D.W./ 
RESULTANT Hb (% ) HAEMOLYSATE ()1L) TRITON-X 100 ()1L) 
0.25 250 0 
0.20 200 SO 
0.15 150 100 
0.10 100 150 
N.B. (i) stock N haemolysate has [Rb] = 100 g/L 
(10%) 
The 0.25% haemolysate was prepared by · 
1/40 dilution i.e. mixing of 25~L 
stock N with 975 ~L diluent 
(D.W./Triton X-lOO). 
(ii) stock P haemolysate has [Hb] = 71.6 g/L 
(7.16%) 
The 0.25% haemolysate was prepared by 
1/28 dilution i.e. mixing 25 ~L stock 
P with 675 ~L diluent (D.W./Triton X). 
Both (i) & (ii) were centrifuged 10000g for 
10 min to remove cell debris prior to the 
preparation of the dilution series of 
haemolysate. 
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experiment. Sample Land H were included ln 
each run of patients' samples to obtain the 
between-run precision data. 
Cross-reactivity 
In the evaluation of cross-reactivity ~f the 
imrnunoturbidimetric assay for CAI, aliquots of 
sample L were spiked with a known amount of 
CAll calibrator (1000 mg/L, Sigma) (-10 times 
normal ECAII concentration) in proportions as 
shown in Table 6 for CAI analysis. 
Recovery 
The procedure involved the addition of known 
amounts of stock CAI standard (1000 .mg/L, 
Sigma Co.) to aliquots of sample L as shown in 
Table 7. The samples were then analyzed for 
CAI. 
comparison-ot-methods experiment 
The comparison-of-methods experiment was 
performed using real patient specimens. A 
group of 15 patient specimens were analyzed by 
both the test method (the imrnunoturbidimetric 
method) and a standard method (the radial 
immunodiffusion method, refer to section 4.-2) 
statistical analyses were performed, using 
student 'st test. Correlation between two 
variables were calculated by linear regression 
analysis. 
4.1.7. DETERMINATION OF HAEMOGLOBIN CONCENTRATION IN 
HAEMOLYSATE 
The determination of haemoglobin (Hb) 
concentration in haemolysate based on the 
principle that haemoglobin is oxidized by 
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Table 6 Preparation of control haemolysates for 
cross-reactivity study 
VOLUME OF VOLUME OF VOLUME OF 
[CAll] SAMPLE L CAll 1% BSA 
SAMPLE ADDED (mg/L) (J.lL) ADDED (J.lL) (J.lL) 
L+BSA 0 380 0 20 
L+CAII 50 380 20 0 
Table 7 Preparation of control haemolysates for recovery 
study 
VOLUME OF 
[CAI] SAMPLE VOLUME OF STOCK VOLUME OF 
SAMPLE ADDED (mg/L) L (J.lL) CAI (1000 mg/L) (J.lL) 1% BSA (J..lL) 
X 0 960 0 40 
X+5 5 960 5 35 
X+10 10 960 10 30 
X+15 15 960 15 25 
X+20 20 960 20 20 
X+25 25 960 25 15 
X+30 30 960 30 10 
X+35 35 960 35 5 
X+40 40 960 40 0 
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potassium ferricyanide to methaemoglobin in 
alkaline pH. The methaemoglobin reacts with 
potassium cyanide to form cyanmethaemoglobin, 
which is measured at 540 nm colorimetrically. 
Modified Drabkin's reagent was used as reagent 
for the assay. It was prepared by dissolving 
2 . 5g of sodium bicarbonate, O. 12 5g of 
potassium cyanide and 0.5g of potassium 
ferricyanide in 1 litre of distilled water. 
The reagent was stable for at least 4 months 
when stored in dark bottle at room 
temperature. Haemoglobin standard was 
obtained from Sigma (525-18) and working 
standard of 9g/L was prepared by dissolving it 
in the modified Drabkin's reagent. The 
analytical procedure was automated using Cobas 
Bio centrifugal analyser (Roche, switzerland) . 
The instrument settings are shown in Table 8. 
The linearity of this method ranges from 
1 g/L to 10 g/L of haemolysate. The between-
run imprecision of haemoglobin measurement was 
2.5%. 
4.1.8. DETERMINATION 
CONCENTRATION 
OF MEAN CELL HAEMOGLOBIN 
The mean cell haemoglobin concentration (MCHC) 
was measured using an automated haematology 
cell count analyser (Technicon H6000, 
Technicon, Tarry town , New York). The analysis 
was performed by the staff of the Haematology 
Department, Prince of Wales Hospital. 
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Table 8 Parameter listing for measurement of 
haemoglobin concentration in haemolysate 
using Cobas-Bio centrifugal analyser (Roche) 
1. UNITS 
2. CALCULATION ·FACTOR 
3 . STANDARD 1 CONCENTRATION 
4. STANDARD 2 CONCENTRATION 
5. STANDARD 3 CONCENTRATION 
6. LIMIT 
7 . TEMPERATURE (oC) 
8. TYPE OF ANALYSIS 
9. WAVELENGTH (nm) 
10. SAMPLE VOLUME (~L) 
11. DILUENT VOLUME (~L) 
12. REAGENT VOLUME (~L) 
13. INCUBATION TIME (second) 
14. START REAGENT VOLUME (~L) 
15. TIME OF FIRST READING (second) 
16. TIME INTERVAL (second) 
17. NUMBER OF READINGS 
18. BLANKING 
19. PRINTOUT MODE 
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g/L 
o 
9 
9 
o 
o 
25 
1 (ENDPOINT MODE) 
540 
10 
50 
90 
10 
o 
0.5 
180 
10 
1 
1 
4.1.9. CALCULATION OF ERYTHROCYTE CARBONIC ANHYDRASE 
I CONCENTRATION 
The erythrocyte carbonic anhydrase I 
concentration can be expressed in g/L of red 
blood cell (RBC) by the following formula. 
ERYTHROCYTE CARBONIC ANHYDRASE I CONCENTRATION(g/L RBC) 
_ Haemolysate carbonic anhydrase I(mg/L)* MCHC (g/dL) 
Haemolysate haemoglobin concentration (g/L) * 100 
4.2 DETERMINATION OF ECAI USING RADIAL 
IMMUNODIFFUSION METHOD 
The determination of ECAI using the single r.adial 
immunodiffusion (RID) technique has been 
previously described (Auton et al., 1976, 
Yamakido et al., 1982). It is cheap and does not 
need sophisticated equipment and is available 
commercially. However , it is very time consuming 
and cannot be automated, thus it is not very 
suitable as a routine test for the diagnosis of 
thyrotoxicosis. In this proj ect, a commercial 
RID method is selected to be a reference method 
for the evaluation of the immunoturbidimetric 
assay for .the ECAI determination~ The kit was 
develo~ed by 'The Binding Site, Ltd., Birmingham, 
England, using polyclonal antiserum. 
The purpose of all immunodiffusion techniques is 
to detect the reaction of antigen and antibody by 
the precipitation reaction. The most important 
determinants of the reaction are the relative 
concentrations of antigen and antibody. Besides, 
the formation of antigen-antibody complexes in a 
semi-solid medium is dependent on buffer 
electrolytes, pH, and temperature (Stites et al., 
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1987). Diffusion reactions in gel have been used 
since 1905 and have been developed into more 
sophisticated techniques. Oudin originally used 
analytical techniques with the diffusion of 
antigens into an antibody containing gel 
(single diffusion) in one direction. Feinberg 
and later Mancini, Carbonara and Heremans 
modified this technique by incorporating the 
antiserum into a thin layer of agar and placing 
the antigen in wells cut into the agar. When 
antigen diffuses from a well into agar containing 
suitably diluted antiserum, initially it is 
present in a relatively high concentration and 
forms soluble complexes; as the antigen diffuses 
radially the concentration continuously .-~-falls 
until the point is reached at which the reactants 
are nearer optimal proportions (at- equivalence) 
and a ring of precipitate is formed (Roitt, 
1991). At equivalence, the diameter and area of 
the ring is related to the antigen concentration 
in the well as shown in Fig 5 (Miller et al., 
1991). Using standard antigen con~~ntrations, a 
calibration curve may be constructed to determine 
unknown concentrations of the same antigen 
(Hudson & Hay, 1989, Roitt, 1991) (Fig. 6). 
The diameter of each ring may be measured either 
directly using a magnifying glass with a 
micrometre scale or calipers with a Vernier scale 
or, after staining, with a plastic ruler. For 
direct measurement, the slide is held over a 
black background, illuminated from the side and 
measurement are made through the glass plate. If 
staining is preferred, the slide may be stained 
with any protein dye such as Coomassie blue. 
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5. RESULTS OF OPTIMIZATION AND EVALUATION EXPERIMENTS 
5.1 OPTIMIZATION RESULTS 
5.1.1. WAVELENGTH 
The absorbance spectrum of 0.5% haemolysate in 
reagent blank mixture was shown in Fig. 7. 
Since haemolysates contain porphyrin and 
related compounds which have high absorbance 
value at 340 , nm, this wavelength (used by 
Cheung & Swaminathan, 1989 for urine samples) 
was considered not . suitable. Wavelengths 
above 600 nm have least background absorbance 
and wavelength of 650 nm was selected to 
monitor the reaction between CAI standards of 
25, 50 and 100 mg against fixed antibody 
titres (1 in 4 & 1 in 8) using 4% PEG" to 
enhance the antigen-antibody reaction. , The 
reaction kinetics were shown in Fig. 8. 
For 1 in 4 antibody dilution, the absorbance 
change at end point (900s) was linear up to 50 
mgjL while antigen excess was evident at 100 
mgjL with lower reaction rate and absence of 
a plateau. 
For 1 in 8 antibody dilution, both 50 mgjL and 
100 mgjL standards showed antigen excess 
phenomenon. The change in absorbance 
monitored at 650 nm were minimal (0.016 for 
the 25 mgjL standard) . 
It seemed unwise to work on too high antibody 
concentration due to the increased occurrence 
of nonspecific binding and the high cost 
incurred. It was decided to optimise the assay 
at a lower ~ntibody dilution by changing the 
wavelength, PEG concentration and sample to 
reagent ratio, the latter two will be 
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discussed later. 
Another wavelength used in turbidimetric 
measurement (Harmoinen, 1987), 450 nm, was 
tested to monitor the reaction between the CAI 
standards of 25, 50 and 100 mgjL against the 
antibody titre of 1 in 8 in 7% PEG. It was 
found that the change in absorbance at 450 nm 
were increased in comparing with 650 nm and 
due to the higher PEG concentration the 
reaction was linear up to 50 mgjL (Fig 9). 
Meanwhile the background absorbance of the 
0.25% haemolysate test sample of 0.3 at this 
wavelength was acceptable. Thus, the 
wavelength of 450 nm was selected for furt·her 
evaluation and patient study. 
5.1.2. PEG CONCENTRATION 
Different PEG concentrations of 4%, 5%, 6% and 
7% were tried for the reaction of different 
concentrations of CAI standards (25, 50 and 
100 mgjL) and antibody dilutions (1 in 4 and 
1 in 8) at 650 nm. The reaction curves were 
shown in Fig. 10. 
By increasing the.PEG concentration to 7%, the 
reaction of CAI standards in antibody dilution 
of 1 in 4 was shown to have linear 
relationship. For antibody dilution of 1 in 
8, significant increase in 'absorbance was 
observed but · antigen excess phenomenon 
occurred at the concentration of 100 mgjL. 
PEG concentrations of 8% and 9% were then 
evaluated to see if further improvement could 
be possible with the higher concentration of 
PEG to speed up the reaction rate and push the 
equivalence zone to a higher antigen 
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FIG.9 REACTION BETWEEN CAI STANDARDS AND 1 IN 8 ANTIBODY 
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concentration. However turbidity and 
precipitates were present ln the reaction 
mixture suggesting the presence of nonspecific 
protein aggregations due to the high PEG 
concentration. Therefore 7% was selected as 
the optimal PEG concentration for the reaction 
between CAI and anti-CAI. 
5.1.3. SAMPLE VOLUME 
The sample volume was varied from 30 ~L to 25, 
20 and 15 ~L for reactions between different 
CAI standards (25, 50 and 100 mg/L) in 
antibody dilutions (1 in 8 and 1 in 16) with 
7% PEG, monitored at 450 nm (Fig.11). 
The reaction 
antibody was 
of the CAI standard and its 
linear up to 100 mg/L if the 
antibody dilution of 1 in 8 was employed using 
15 ~L sample volume. For the 1 in 16 antibody 
dilution, the reaction was also improved on 
the decreasing of the sample volume. The 
linearity of the reaction was able to reach 50 
mg/L level when the sample volume was 
decreased to 20 ~L or 15 ~L. If the 
haemolysate concentration of the patients' 
samples can be adjusted .to around 0.20%, the 
ECAI concentration will fall within the 
workable linearity range of 50 mg/L. Thus, 
the sample volume of 15 ~L can be used with 
the antibody dilution of 1 in ' 16 to obtain the 
workable linearity range of CAI up to 50 mg/L. 
5.1.4. ANTIBODY DILUTION 
Part of the optimization concerning antibody 
dilution have been mentioned previously when 
discussing optimization procedures for other 
parameters. As a high antibody concentration 
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will be costly and introduces nonspecific 
binding, attempts will be made to optimise the 
assay at a more diluted antibody 
concentration. 
As shown in Fig.8, a linear response up to 50 
mg/L was observed with an antibody dilution of 
1 in 4. By adding PEG up to 7%, linearity up 
to 50 mg/L was achieved using Ab dilution of 
1 in 8 (Fig .10b) . The change to 450 nm 
wavelength for monitoring significantly 
improved the absorbance change (F ig . 9) . 
Finally the selection of a low sample volume 
(15 J..LL compared 30 J..LL) allowed the use of 
aritibody dilution of 1 in 16 in the assay ~ with 
a linearity of up to 50 mg/L (Fig.11b). 
5.1.5. TEMPERATURE 
The reaction between different CA! 
concentrations (25, 50 and 100 mg/L) and 
antibody of 1 in 16 in 7% PEG'were incubated 
at 25, 30 and 37°C to optimize the temperature 
requirement. The reactions were shown in 
Fig.12. At 37°C, the absorbance change 
results were more correlated with the increase 
in CA! standard value -from 25 to 50 mg/L than 
at 25°C or 30°C. Thus 37°C was chosen as the 
optimal temperature to work with in this 
reaction. 
5.1.6. TIME OF INCUBATION 
For low CAI concentration (less than 30 mg/L) , 
the reaction reached endpoint (a plateau) 
beyond 400 seconds whereas for higher 
concentration (more than 30 mg/L) , the plateau 
was reached beyond 700 seconds and the 
absorbance value remained stable all the way 
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through 900 seconds. Therefore the time of 
incubation can be any time interval between 
700 and 900 seconds. In this setup, the time 
of incubation was chosen to be 900 seconds. 
5.1.7. OPTIMIZED TEST PROTOCOL 
The optimized test protocol for the 
determination of CA! in haemolysate using 
immunoturbidimetric assay was listed in Table 
9. The reagent composed of 1 in 16 antibody 
dilution in 7% PEG. DENS/Plot program was 
used (Type of analysis = 7.5) with calibration 
curve generated from six CA! standards. The 
initial CAI standards used were 1.25, 2.5, 5, 
10', 30 and 50 mg/L. During the evalu·ation 
studies, it was found that the CAI standards 
of 1.25 and 2.5 mg/L did not have reproducible 
reaction results. Thus, the six CAI standards 
were finalised as 5, 10, 20, 30, 40 and 50 
mg/L. Since CAI of 0.25% haemolysate of 
thyrotoxic patients will seldom fall below 5 
mg/L, 5 mg/L was selected to be the lowest 
standard. 
5.2 EVALUATION RESULTS 
5.2 • 1 STABILITY 
During the whole working period of roughly 6 
months, the reaction rates of different 
aliquots of frozen standards and controls have 
been quite constant. For example the 
coefficients of variation of ~so of control 
Land Hand 50 mg/L standard are 11.1% (n= 28, 
mean= 0.013 ), 4.9% (n= 28, mean= 0.036) and 
6.8% (n= 10, mean= 0.040). Also, the CA! 
calibrator H for RID measured immediately 
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Table 9 Parameter listing for CAI measurement after 
optimization 
1 
2 
3 
3 
3 
3 
3 
3 
6 
7 
8 
9 
. 10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
UNITS 
CALCULATION FACTOR 
STANDARD 1 .CONC 
STANDARD 2 CONC 
STANDARD 3 CONC 
STANDARD 4 CONC 
STANDARD 5 CONC 
STANDARD 6 CONC 
LIMIT 
TEMPERATURE [DEG.C] 
TYPE OF ANALYSIS 
WAVELENGTH [NM] 
SAMPLE VOLUME [UL] 
DILUENT. VOLUME [UL] 
REAGENT VOLUME [UL] 
INCUBATION TIME [SEC] 
START REAGENT VOLUME [UL] 
TIME OF FIRST READING [SEC] 
TIME INTERVAL [SEC] 
NUMBER OF READINGS 
BLANKING MODE 
PRINTOUT MODE 
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MG/L 
5000 
5.0 
10 
20 
30 
40 
50 
o 
37.0 
7.5 
450 
15 
10 
150 
10 
o 
1.0 
30 
30 
1 
1 
after reconstitution and after six months 
storage at -40°C had reproducible ring 
diameters in the RID setup. Therefore, CAI 
and its antibody were stable for at least 6 
months or even longer if they were properly 
stored. 
5 • 2 • 2 LINEARITY 
The linearity curve of the aqueous CAI 
standards was shown in Fig.13. 
It was found that the reaction of CAI in 
. antibody dilution of 1 in 16 was linear up to 
50 mg/L, beyond which it flattened and then 
declined due to antigen excess. 
Table 10 showed the measured CAI 
concentrations 
mg/L. It was 
of CAI standards of 0 to 9 
evident that the assay was 
unreliable at values below 5 mg/L, which is 
also the lowest standard used. Hence 5 mg/L 
was taken as the lowest detection limit 
beyond which a more concentrated haemolysate 
preparation (e.g. 0.3%) was required to obtain 
an CAI result within the workable range. such 
a low concentration of CAI is seldom 
encountered especially if the haemolysate 
concentration is around 0.25%. 
The effects of different diluents (D.W. and 
0.1% Triton-X) on the imrnunoturbidimetric 
reaction of CAI in antibody dilution of 1 in 
16 in P and N were shown in Fig .14. The 
results of the dilution series showed linear 
relationship. It implied that the haemolysate 
matrix did not affect the immunoturbidimetric 
method when haemolysate range of 0.10% to 
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FIG.13 LINEARITY CURVE OF AQUEOUS CAI STDS 
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Table 10 sensitivity testing of the immunoturbidimetric 
assay for CAI determination 
CAI 
STANDARD mgjL 
9 
8 
7 
6 
5 
4 
3 
2 
o (1% BSA) 
- 60 -
OBSERVED 
[CAI] mgjL 
8.94 
8.01 
7.20 
6.70 
4.70 
4.10 
3.90 
1.60 
SIGN 
FIG. t4 EFFECT OF HAEMOLYSATE DILUENT(D.W./TRITON X-1 00) 
ON CAI DETERMINATION OF PATIENTS' SAMPLES 
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0.25% was used. It 
haemolysate prepared 
was also found 
in both diluents 
that 
have 
similar ECAI results. Consequently Triton X-
100, although not used in this study, is also 
a suitable haemolysing agent for this assay. 
5.2 .3 PRECISION 
5.2.3.1 WITHIN-RUN 
5.2.3.2 
The within-run imprecision of the assay 
estimated using pooled haemolysate samples 
L, M and H were 8.3, 2.3 and 3.8% 
respectively (Table 11). 
The wi'thin-run imprecision data of the ECAI 
( including Hb measurement ) was.- also 
acceptable showing that the haemoglobin 
determination did not add much error to the 
imprecision. 
BETWEEN-RUN 
The between-run imprecision of the assay 
estimated using pooled haemolysate samples 
of Land H were 9.9 and 6.3% respectively 
(Table 12). 
~ 5.2.4 CROSS-REACTIVITY 
The CAI concentration of the spiked sample ( 
50 mg/L CAII - about 10 times normal ECAII 
concentration) showed no difference with the 
original one indicating that this 
immunoturbidimetric assay is not interfered by 
CAII at an antibody dilution of 1 in 16. 
5 • 2 • 5 RECOVERY 
The recovery as estimated by spiking various 
amounts of standard to sample L were 88.0 -
106.4%. 
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Table 11 within-run imprecision of automated assay (n=15) 
CONTROL 
SAMPLE ANALYTES Mean SD CV(%) 
L CAI (mgjL) 10.48 0.86 8.25 
Rb (gjL) 2.59 0.06 2.26 
ECAI (mgjgHb) 4.05 0.34 8.48 
M CAI (mgjL) 28.05 0.65 2.31 
Rb (gjL) 2.69 0.03 1.16 
ECAI (mgjgHb) 10.41 0.26 2.53 
H CAI (mgjL) 42.95 1.62 3.76 
Hb (gjL) 2.70 0.05 1.72 
ECAI (mgjgHb) 15.92 0.51 3.21 
~".:- .. 
N.B. If the outlier (> 2 S.D.) in control sample L 
is omitted, the mean of CAI concentration will 
become 10.63 mgjL, S.D. will be 0.66 and the % 
cv will be 6.24. 
Table 12 Between-run imprecision of automated assay (n=29) 
Control Sample . Analytes Mean S.D. CV(%) 
L CAI (mgjL) 10.48 1.03 9.87 
Hb (gjL) 2.56 0.07 2.81 
ECAI (mgjgRb) 4.09 0.41 10.02 
H CAI (mgjL) 42.99 2.70 6.29 
Hb (g/L) 2.68 0.06 2.31 
ECAI (mgjgRb) 16.05 1.14 7.09 
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5.2.6 COMPARISON WITH COMPARATIVE METHOD 
The automated immunoturbidimetric assay for 
the ECAI determination was compared with a RID 
method. The results correlated well (r=0.981, 
p<O.OOOl) (Fig.15). Regression analysis gave 
the following relationship : 
[ECAI]AWlmation method (mg/gHb) = 1.3 [ECAI]RJD (mg/gHb) - 1.10 (n=15) 
5. 3 DISCUSSION 
The optimized immunoturbidimetric assay for CAI 
determination in haemolysate was satisfactory for 
routine use. The results of the evaluation 
studies were acceptable with reasonable 
imprecision, recovery and cross-reactivity. 
However, due to the low titre of the commercial 
anti-CAI preparation, the antibody dilution used 
was lower than expected. Also, the linearity of 
the workable range was limited to 50 mg/L even 
with the use of 7% PEG as enhancer. Thus, the 
assay can be improved if higher "titre antibody 
preparation is available. 
In the presence of excess antigen, 
immunoturbidimetric assays will underestimate the 
results due to ressolution of the antigen- · 
antibody complex. To avoid this prozone effect, 
the samples can be tested in two dilutions to see 
whether there is an increase in reaction rate in 
the sample with higher dilution ratio. 
Due to the limited availability of RID plates, 
only 15 samples (7 thyrotoxic patients and 8 
normal subjects) were used in the correlation 
study. ECAII were also determined for these 15 
subj ects by RID method and did not show any 
significant difference between the thyrotoxic 
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FIG.15 CORRELATION BETWEEN ECAI MEASURED BY RADIAL 
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group and the normal sUbjects. The correlation 
coefficient of the two methods was close to 1.0 
indicating that the immunoturbidimetric technique 
is comparable to a standard technique. Thus the 
automated immunoturbidimetric assay for the CAI 
determination in haemolysate is an alternative to 
RID method and is particularly useful in routine 
determination for the diagnosis of 
thyrotoxicosis. 
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6. ECAI IN NORMAL SUBJECTS 
6.1 SUBJECTS AND METHOD 
No attempts was made to establish a population 
reference range for ECAI using our method due to 
the limited scope of the proj ect. However, 7 
male and 12 female hospital staff were recruited 
as normal controls in the patient study. The age 
ranged from 24 to 55 years and fasting samples 
were collected after 15 minutes of rest. 
6.2 RESULTS 
The mean, 
the ECAI 
standard deviation (SO) and range of 
results were shown in Table 13. 
Reference ranges quoted in literature are 
included for comparison. 
6.3 DISCUSSION 
The immunological levels of ECAI of the normal 
controls when expressed in mg/gHb were in close 
agreement with the quoted reference range 
determined by Auton et al. using RID method. 
Also, the mean ECAI concentration _of which was 
similar to those obtained by Kondo et al. using 
RID method and Shepherd et al. using ELISA 
method. This suggested that the results of ECAI 
obtained by immunoturbidimetric method were 
co.mparable t o other· methods including RID and 
.ELISA done by other groups of investigators. 
ECAI concentration may vary with age in the 
paediatric age group. Shepherd et al. found that 
the mean (SO) ECAI concentration was 1.93 (0.93) 
mg / gHb in neonates. Also, ECAI concentration 
rises gradually with age, approaching normal 
adult levels by 16 years (Shepherd et al., 1985). 
Thus a different reference range should be 
established for neonates and children. 
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Table 13 Results of ECAI in normal subjects 
n MEAN SO RANGE METHOD REFERENCE 
ECAI Imruno-
(g/l RBC) 19 5.07 0.64 3.79-6.35 turbidimetry 
(mg/g Hb) 19 15.1 2.10 10.9-19.3 
ECAI RID Auton .et al. 
(mg/g Hb) 90 11.1-22.5 1976 
ECAI RID Kondo et al. 
(rng/g Hb) 8 14.4 1984 
ECAI ELISA She~.erd 
male (mg/g Hb) 20 16.9 3.4 et al. 1982 
female (mg/g Hb) 20 15.4 2. 1 
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7 • PATIENT STUDY 
In the patient study, the ECAI results of thyrotoxic 
patients will be compared to those of normal sUbjects. 
The relationship between the ECAI and FT3 would be 
investigated. Also, the correlation between the 
ECAI and EZN of the patients (both before and after 
treatment) would be evaluated. A typical example of 
the changes in the levels of ECAI and FT3 following 
treatment of thyrotoxicosis would then be examined. 
7.1 SUBJECTS AND METHOD 
Fifty hyperthyroid subjects of the clinical study 
carried out by Shek were investigated (Shek, 
1989). They were recruited before treatment both 
from the hospital wards and outpatients 
departments in Prince of Wales Hospital, Shatin, 
Hong Kong. When the patients were first seen, a 
thorough clinical assessment including history 
and physical examination was taken. Verbal 
consent for the recruitment into study was 
obtained. A panel of TFTs (FT3 & TSH) was 
_. _requested together with the usual radiological 
and laboratory investigations. Two weeks later, 
the patients were reviewed with the investigation 
results. If hyperthyroidism was confirmed 
biochemically, pretreatment EZN was measured and 
the remaining of the specimen was kept for ECAI 
determination. Antithyroid drug (carbimazole) 
was started and the patients were regularly 
followed up. During each follow up visit, the 
patient was reassessed for thyroid functional 
status and the dosage of antithyroid drug was 
titrated against the clinical and biochemical 
response. Depending on clinical need, the drug 
treatment might be changed to propylthiouracil, 
or the patient referred for surgical or 
radio iodine treatment. EZN, TSH, and FT3 were 
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monitored in every follow up visit and packed 
cell samples were saved for ECAI. All 50 
patients were seen and managed by a single 
physician during the whole study period (Shek, 
1989). EZN was measured by an atomic absorption 
spectrophotometer (Varian AA-1475 series, 
Springvale, Australia), TSH was measured by a 
sensitive chemiluminescence method (Magic Lite 
TSH, Ciba Corning, Medfield, USA), FT3 was 
measured by radioimmunoassay (Coat-A-Count FT3, 
Diagnostic Products Corporation, USA). Between-
run coefficients of variation for TSH and FT3 
were <5% and <10% respectively. 
ECAI in these subjects were measured at the end 
of the clinical study. Specimens from _the same 
patient were measured in the same batch, with the 
aim to minimize variations due to between-run 
imprecision. 
7.2 RESULTS 
7.2.1 DEMOGRAPHIC AND BIOCHEMICAL PARAMETERS 
Of the 50 untreated thyrotoxic new patients, 
there were 4 males and 46 females. The age 
ranged from 17 to 54 years with mean and 
median of 33.7- and ,34 years respectively. 49 
were suffered from Graves' disease while one 
had a toxic thyroid adenoma. Surgical 
treatment was refused in the patient with 
adenoma. All of them ' had symptoms of 
thyrotoxicosis ' for more than 3 months. The 
results of one patient was ignored as he 
suffered from thalassaemia, a known cause for 
elevated ECAI (Lie-Injo et al., 1970). At 
presentation, their FT3 (mean: 15.8 pmol/L, 
SD: 6.8, RR: 2.2-6.3) and TSH results (mean: 
0.07 mIU/L, SD: 0.1, RR: 0.3-0.4) were 
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comparable with thyrotoxicosis. ECAI (mean: 
1.95 g/L RBC, SD: 0.88)was significantly lower 
than that the normal control group (mean: 5.07 
g / 1 RBC, S D : 0 . 64 ) ( p< 0 . 001). Fig. 16 showed 
the levels of ECAI in thyrotoxic patients and 
control sUbjects. There was a slight 
overlapping between the two populations. 
7 .2 .2 CORRELATION BETWEEN ECAI AND FT3 RESULTS OF 
THYROTOXIC PATIENTS BEFORE TREATMENT 
Fig. 17 showed the relationship between FT3 
and ECAI at presentation. There is a negative 
correlation between FT3 and ECAI· (r= - 0.487, 
P< 0 . 001). This negative correlation between 
FT3 and ECAI was comparable to the findings of 
a negative correlation between FT3 ' and EZN 
(r=-0.34, p<0.02) (Shek, 1989). 
7 • 2 • 3 CORRELATION BETWEEN ECAI AND EZN RESULTS OF 
THYROTOXIC PATIENTS 
The ECAI results were correlated with the 
corresponding EZN results of the 49 
thyrotoxic patients (before and after 
treatment) . Fig. 18 showed the correlation 
between the two parameters. There was a 
significant positive correlation between ECAI 
and EZN (r=0.866, p<0.0001). The regression 
analysis giving the following relationship: 
ECAI (g/L RBC) - 0.03 EZN (~mol/L RBC) - 1.03 
(n=355) . 
7.2.4. RELATIONSHIP BETWEEN THE CHANGES IN' ECAI AND 
FT3 RESULTS IN THYROTOXIC PATIENT ON TREATMENT 
The relative changes in the levels of ECAI and 
FT3 in a typical patient undergoing treatment 
was shown in Fig.19. It indicated the reverse 
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FIG.16 ECAI LEVELS IN THYROTOXIC PATIENTS & CONTROL SUBJECTS 
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FIG.17 CORRELATION BETWEEN ECAI & FT3 IN UNTREATED 
THYROTOXIC PATIENTS 
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FIG.18 CORRELATION BETWEEN ECAI & EZN IN THYROTOXIC 
PATIENTS 
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FIG.19 CHANGES IN ECAI & FT3 LEVELS IN A THYROTOXIC 
PATIENT UNDERGOING TREATMENT 
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relationship between the two parameters. 
ECAI, similar to EZN and TSH, had a delayed 
response while FT3 responded rapidly to the 
treatment. 
7 • 3 DISCUSSION 
The patient study aimed at evaluating the use of 
ECAI in the diagnosis of thyrotoxicosis. ECAI 
measures a tissue effect of thyroid hormone and 
if its usefulness can be established, it can be 
a useful adjunct to the existing TFTs in 
diagnosing thyrotoxicosis in problem situations. 
All the patients in the . study had been 
symptomatic for more than 3 months. Their ECAI 
was shown to be low when compared to the normal 
control with minimal overlap. The ECAI values 
were negatively related to FT3. The usefulness 
of ECAI in diagnosing thyrotoxicosis will not be 
limited by the 3 months of symptoms since 
patients referred to the thyroid clinic seldom 
have symptoms shorter than this period. In this 
study, the ECAI levels of thyrotoxic patient 
group were compared to a limited number of 
control subjects. " In order to apply the test for 
. routine use, a proper population reference range 
"." ·$hould be established. . :·The study also 
demonstrated that ECAI correlated well with EZN 
results. The regression equation between EZN and 
ECAI showed that 0.03g of ECAI contains 1 ~mol of 
zinc. As the molecular weight of carbonic 
anhydrase is 30000, 0.03g of ECAI contains 
0.03/30000 mole or l~mol of ECAI. Therefore ECAI 
and EZN are in 1:1 ratio which is compatible with 
results from other investigators (Tashian and 
Hewett-Emmett, 1984; Rockett, 1985). 
The determination of ECAI is a better alternative 
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to that of EZN since immunoturbidimetric method 
can be easily automated in a centrifugal analyzer 
commonly available in routine diagnostic 
laboratory. However, the measurement of zinc by 
atomic absorption method cannot, at leas~ at the 
present moment, be automated. The ECAI levels 
when e~pressed in mg/g Hb correlated equally well 
with the EZN (j.Lmol/l RBC) and FT3. Also, ECAI 
levels (mg/gHb) obtained by this 
immunoturbidimetric assay correlated well with 
RID. The ECAI results of the normal subj ects 
were consistent with the ones obtained by other 
groups of investigators using RID or ELISA 
method. If ECAI is expressed in mg/gHb, its 
measurement will only involve two an~lytical 
procedures, namely haemolysate CAI content and 
haemolysate haemoglobin content. This will 
reduce the overall analytical variability. 
During treatment, FT3 responded rapidly whereas 
the response of ECAI was delayed. Similar 
delayed response patterns were also observed in 
EZN (Shek, 1989). Shek showed that it took 16-17 
weeks for half of the patients to normalize the 
EZN, it can be expected that ECAI will require 
similar time. Therefore, ECAI cannot be used to 
follow up patients during antithyroid treatment. 
This delay is probably due to the fact that 
enzyme synthesis in erythrocyte only occurs in 
developing stage and therefore the inhibitory 
effect of thyroid hormone on ECAI synthesis only 
affect new red cells. Consequently, ECAI will 
only return to normal when the cells circulating 
before treatment have been 
lifespan of erythrocytes 
(Swaminathan et al., 1976). 
replaced (average 
is 120 days) 
This delayed response of ECAI to rapidly changing 
thyroid status limits its use for monitoring 
treatment. On the other hand, this can be an 
advantage as it can distinguish between transient 
and well established hyperthyroidism~ In 
patients with transient hyperthyroidism, the ECAI 
level will not be suppressed as it takes several 
months for the ,existing red cells to be totally 
replaced by the newly synthesized cells which 
have low ECAI content. 
In conclusion ECAI, similar to EZN, is a useful 
tissue marker in hyperthyroidism. with the 
esta,blis'hment ~f a population reference range, 
ECAI can be a better alternative to EZN due to 
the ease of automation and the theoretical 
advantage of directly measuring the tissue 
effect. ECAI reflects the functional thyroid 
status for the previous few months and hence 'is 
capable of distinguishing transient from well 
established hyperthyroidism. 
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8. GENERAL DISCUSSION 
ECAI is a better marker than EZN in reflecting 
functional thyroid status. Most of the zinc content 
in human erythrocytes exists in association with CAI 
about 20% is bound to CAll, superoxide dismutase, and 
other enzymes or is present in an available form (Ohno 
et al., 1985). Therefore, the change in EZN may not 
always be associated with that of ECAI. In blood, CAI 
is present only in erythrocytes but zinc is present in 
plasma, erythrocytes, leukocytes and platelets. As 
leukocytes have many-fold higher zinc concentrations 
than erythrocytes (Bogden, 1980), sufficient care must 
be taken to remove plasma, leukocytes and platelets 
from the blood sample to obtain a reliable EZN .result. 
The determination of ECAI also has advantages o-ver EZN 
in that the assay can be automated and hence with 
faster turnaround time. The instrumentation required 
is a centrifugal analyzer which is more commonly 
available in routine laboratory than atomic absorption 
spectrophotometer. Besides, less technical expertise 
is required and the hazard of the use of compressed 
acetylene which is highly flammable is eliminated. If 
ECAI is expressed in mg/gHb, the determination of MCHC 
can be omitted. This may further reduce the 
analytical variability. 
Despite of the above advantages, there are problems in 
the ECAI assay. For example, the commercial antibody 
preparation is costly and relatively weak. In order 
to have a reliable source of cheaper and more potent 
antibody in-house preparation of the antibody can be 
a possible solution. Experimental animals such as 
rabbits can be immunized by pure human CAI either 
commercially with .purity checked by SDS~polyacrylamide 
gel electrophor~sis or from blood CAI after 
purification procedure described by Drescher 
(Drescher, 1978). After the appropriate time 
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interval, the blood of the animals can be taken and 
tested for the presence of anti-human CAI. The 
animals will then be injected with a booster dose to 
get secondary immune response. The anti -human CAI can 
then be harvested and purified using preparative 
isoelectric focusing technique (Hudson & Hay, 1989). 
It is possible to obtain sufficient ultrapure material 
by this route for the preparation of antibody. The 
strength and cross~reactivity of the purified antibody 
will be examined before use. Thus, both the yield and 
the strength of the antibody which is the main reagent 
will be under the user's control. If the strength of 
antibody is increased, the linearity of the workable 
range can be extended e.g. to 100 mg/L and the Hook 
effect of antigen excess will not occur for 0.25% 
haemolysate samples. Though the equipment required 
for the purification of antigen and/or antibody is 
expensive, it will be worthwhile for the long term 
cost-effectiveness of the assay. 
Another problem with the ECAI assay is the lack of 
proper quality control materials. Although pooled 
haemolysates from patients and normal individuals can 
be used as internal quality control materials, there 
is no commercial available quality control material 
for comparison. 
The patient study has shown that ECAI is useful in the 
diagnosis of thyrotoxicosis. However, caution has to 
be taken when interpreting ECAI results in the 
paediatric age groups. In" neonates and children, a 
different reference range is required since the normal 
neonatal mean of ECAI (Shepherd et al., 1985) is about 
one-eighth of the normal adult mean and its level will 
rise gradually with age until 16 years of age to reach 
the adult level. 
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Apart from thyroid function, there are other 
conditions affecting the ECAI concentration (Table 1) . 
For example, chronic renal disease, chronic 
haemodialysis and the use of carbonic anhydrase 
inhibitors will induce elevations in ECAI levels 
(Yamakido et al., 1982; Goriki et al., 1982; Walker et 
al., 1984).° Therefore, in patients with concomitant 
disorders listed in Table 1. ECAI levels should be 
interpreted with care. Most of these conditions are 
associated with elevated ECAI, thus making a low 
erythrocyte carbonic anhydrase I concentration a 
highly predictive indicator of thyrotoxicosis. 
In hypothyroidism, the ECAI will be elevated. However 
the separation between hypothyroid and euthyroid was 
less distinct and there is a certain degree of 
overlap. Apart from hypothyroidism, many other 
conditions are associated with elevated ECAI. This 
makes the role of ECAI in diagnosing hypothyroidism 
being questionable. 
ECAI levels depend both on the degree and the duration 
of thyrotoxicosis (Shek, 1989). Though it is not 
useful in the diagnosis of very early thyrotoxicosis, 
it can distinguish between established and transient 
hyperthyroidism. The usefulness of EZN (and therefore 
ECAI) in the differential diagnosis of hyperthyroidism 
in patients with hyperemesis gravidarum has been 
reported by Lao et al. (Lao et al., 1987). · Some 
pregnant women with hyperemesis gravidarum also 
suffered from transient hyperthyroidism which settles 
when the hyperemesis gravidarum is treated. Patients 
with this syndrome usually do not require antithyroid 
treatment. However, it may be difficult to 
distinguish these patients from those who have 
established thyrotoxicosis presenting during 
pregnancy. Since patients with established 
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thyrotoxicosis have low EZN (and ECAI) whereas 
patients with transient hyperthyroidism associated 
wi th hyperemesis gravidarum have normal EZN (and 
ECAI) , a distinction between the two groups can be 
made based on the EZN or ECAI level. 
In conclusion, the immunological level of ECAI can be 
determined by an a~tomated immunoturbidimetric method 
using a centrifugal analyzer. The results are 
comparable with other standard methods like radial 
immunodiffusion. The ease of operation and fast 
turnaround time make ECAI a better tissue marker over 
EZN for the diagnosis of thyrotoxicosis in a routine 
laboratory. 
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